stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) Debt to equity
BridgeBio Pharma, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was −1.2×, down 0.3× from fiscal 2025 (−0.9×). Over the past ten years it has ranged from −2.0× (fiscal 2021) to 4.5× (fiscal 2020); the current reading is higher than 56% of that period. That is below the Biotechnology industry median of 0.0× and below the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | −0.9× | — |
| FY2024 | −1.2× | — |
| FY2023 | −1.3× | — |
| FY2022 | −1.4× | — |
| FY2021 | −2.0× | — |
| FY2020 | 4.5× | 2,033.00% |
| FY2019 | 0.2× | 45.74% |
| FY2018 | 0.1× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | −1.2× | — |
| Jun 2026 | −0.8× | — |
| Mar 2026 | −0.8× | — |
| Dec 2025 | −0.9× | — |
| 30 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| HALO Halozyme Therapeutics, Inc. compare | −58.8× |
| BBIO BridgeBio Pharma, Inc. | −1.2× |
| EXEL Exelixis, Inc. compare | 0.0× |
| SMMT Summit Therapeutics PLC compare | 0.0× |
| KYMR Kymera Therapeutics, Inc. compare | 0.0× |
| TECH Bio-Techne Corp compare | 0.1× |
| ASND Ascendis Pharma A/S compare | 0.3× |
| BMRN BioMarin Pharmaceutical Inc. compare | 0.7× |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.3× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on BBIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement